Alprostadil (Caverject/MUSE) Pediatric (Under 12) Dosing

What Alprostadil Formulations Exist and Which Apply to Children Under 12

Three commercially distinct alprostadil formulations are on the U.S. market, and they serve entirely different patient populations. Caverject (Pfizer) is an intracavernosal injectable indicated for adult male erectile dysfunction. MUSE (Meda Pharmaceuticals) is an intraurethral suppository with the same adult ED indication. Prostin VR Pediatric (alprostadil sterile solution for IV infusion) is the only formulation carrying an FDA-approved pediatric indication, specifically for neonates with congenital heart defects that depend on a patent ductus arteriosus for pulmonary or systemic perfusion. [1]

No published randomized controlled trial, case series, or FDA-cleared protocol exists for Caverject or MUSE in any patient under 18. The FDA prescribing information for Caverject states explicitly that the drug "is not indicated for use in pediatric patients." [2] MUSE labeling mirrors this restriction. [3] Any clinician encountering a query about Caverject or MUSE dosing in a child under 12 should document that no approved dosing exists and that use would constitute an unapproved off-label application with no established safety data in that population.

For the purposes of this article, the clinically actionable pediatric dosing discussion therefore centers on Prostin VR Pediatric, the IV formulation of alprostadil (prostaglandin E1, PGE1), which is the formulation legitimately used in neonatal and pediatric cardiac intensive care units. [4]

FDA-Approved Indication for Alprostadil in Neonates and Young Children

The only sanctioned indication for alprostadil in patients under 12 is temporary maintenance of ductus arteriosus patency in neonates with ductus-dependent congenital heart disease, pending corrective or palliative surgery. [1] Ductus-dependent lesions include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot with severe right ventricular outflow obstruction, transposition of the great arteries, interrupted aortic arch, coarctation of the aorta, and hypoplastic left heart syndrome. [5]

The American Heart Association's 2021 guidelines on management of congenital heart disease categorize PGE1 infusion as a Class I recommendation (Level of Evidence B-NR) for stabilization of neonates with suspected ductus-dependent lesions before surgical intervention. [6] The Pediatric Advanced Life Support (PALS) guidelines from the American Heart Association similarly list prostaglandin E1 as a first-line agent in this setting. [7]

PGE1 works by relaxing the smooth muscle of the ductus arteriosus wall through cyclic AMP-mediated pathways, keeping the vessel open. [8] In term neonates, the ductus typically closes within 10 to 15 hours of birth under normal conditions. PGE1 reverses or prevents this closure, which in ductus-dependent anatomy can be life-saving within minutes. [9]

Weight-Based IV Dosing Protocol for Prostin VR Pediatric

The standard starting dose is 0.05 mcg/kg/min administered as a continuous IV infusion. [1] If the therapeutic response (assessed by improvement in arterial oxygen tension or blood pressure) is inadequate after 15 to 30 minutes, the infusion rate may be increased to 0.1 mcg/kg/min. [10] Doses as high as 0.4 mcg/kg/min have been used in resistant cases, though adverse-effect frequency increases substantially at rates above 0.1 mcg/kg/min. [1]

Once a satisfactory response is achieved, the maintenance dose should be reduced to the lowest effective rate, often 0.01 to 0.02 mcg/kg/min. This titration-to-effect approach is standard practice in neonatal ICU protocols across major academic centers. [11] The drug is typically diluted in normal saline or dextrose 5% in water and delivered through a central umbilical artery catheter or peripheral IV line, though umbilical artery catheters are preferred in critically ill neonates for concurrent hemodynamic monitoring. [12]

A 2019 Cochrane review examining prostaglandin use in congenital heart disease noted that observational data consistently support ductal reopening in 60 to 90% of neonates treated within 96 hours of ductal closure, though randomized trial data in this population are ethically constrained. [13] The review emphasized that dose titration should be individualized based on oxygenation response, not body weight alone.

Specific preparation: Prostin VR Pediatric is supplied as a 500 mcg/mL concentrate. For a 3 kg neonate requiring 0.05 mcg/kg/min, the calculated rate is 0.05 mcg x 3 kg x 60 min = 9 mcg/hour. Diluting 1 mL of concentrate in 99 mL NS yields 5 mcg/mL; that solution infuses at 1.8 mL/hour for this patient. [10]

Adverse Effects and Monitoring Requirements in Pediatric Patients

Apnea is the most clinically serious adverse effect in neonates. The original FDA labeling reports apnea in approximately 10 to 12% of neonates receiving PGE1, with highest incidence in those weighing <2 kg at birth. [1] Respiratory support equipment must be immediately available at the bedside before infusion begins, a requirement explicitly stated in the FDA prescribing information. [1]

Other adverse effects in pediatric patients include fever (reported in 14% of neonates in early clinical series), hypotension (reported in 4%), bradycardia (reported in 7%), and seizures (reported in 4%). [14] Prolonged infusions lasting more than 120 hours have been associated with cortical proliferation of long bones (periosteal reaction), a reversible effect that typically resolves after the drug is discontinued. [15]

Continuous monitoring parameters during Prostin VR Pediatric infusion include arterial oxygen saturation (pulse oximetry and/or arterial blood gas sampling), heart rate, blood pressure, respiratory rate, and temperature. [1] In neonates with systemic left-heart-dependent lesions, blood pressure in the descending aorta is the primary efficacy endpoint. In neonates with pulmonary-dependent lesions, pO2 is the primary endpoint. [6]

A 2022 review in Pediatric Cardiology reported that apnea episodes occurred a median of 40 minutes after infusion initiation, supporting a minimum 60-minute bedside observation window after any dose increase. [16]

Why Caverject and MUSE Have No Role in Patients Under 12

Erectile dysfunction, the approved adult indication for Caverject and MUSE, is by definition absent as a clinical entity in prepubertal children. The physiological mechanism requiring alprostadil's smooth-muscle relaxation in penile erectile tissue does not apply to this age group. [2] [3]

Linet and colleagues published the landmark Caverject efficacy trial in the New England Journal of Medicine in 1996, enrolling men with refractory ED who had failed other therapies. That trial (N=296 for the dose-finding phase, with the key phase N=683) demonstrated that intracavernosal alprostadil produced erections sufficient for intercourse in approximately 70% of men at doses between 2.5 and 20 mcg. [17] The study enrolled no patients under 18, and its findings cannot be extrapolated to pediatric populations for any indication.

MUSE (medicated urethral system for erection) delivers 125 to 1 to 000 mcg alprostadil suppositories intraurethrally. A 1997 New England Journal of Medicine trial by Padma-Nathan and colleagues (N=1,511) confirmed efficacy in adult men with ED of neurogenic, vasculogenic, or mixed etiology. [18] Again, no patient under 18 was enrolled, and urethral anatomy in children under 12 makes this delivery route clinically inappropriate.

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies when a drug is approved for an adult indication that is also relevant in children. Because ED is not a pediatric condition, no PREA requirement applies to Caverject or MUSE, and no manufacturer-sponsored pediatric study has been conducted or is pending. [19]

Off-Label Pediatric Uses of Alprostadil Beyond Cardiac Indications

Outside neonatal cardiology, alprostadil has been studied in a small number of off-label pediatric contexts, though none involve Caverject or MUSE. [20]

Pulmonary hypertension in neonates and infants: Several case reports and small case series (total N <50 across published literature through 2023) describe PGE1 infusion as a bridge therapy in neonatal pulmonary arterial hypertension refractory to inhaled nitric oxide and sildenafil. Doses used in these reports ranged from 0.01 to 0.05 mcg/kg/min, mirroring the low end of the ductal-patency protocol. [21]

Peripheral vascular insufficiency in children: A 2018 case report in the Journal of Pediatric Surgery described PGE1 infusion at 0.03 mcg/kg/min in a 7-year-old with Raynaud's phenomenon secondary to systemic sclerosis, with partial symptom relief. [22] No controlled data exist for this use.

Necrotizing enterocolitis (NEC): Preclinical data suggest PGE1 may improve mesenteric perfusion, but no human pediatric trial has been completed as of the article's review date. [23]

The table below summarizes a clinical decision framework for alprostadil use across pediatric age bands, intended to assist practitioners in quickly identifying whether any alprostadil use is appropriate for a given patient. The HealthRX medical team developed this framework from FDA labeling, AHA guidelines, and published case-series data; it has not been validated in a prospective study.

Alprostadil Pediatric Decision Framework

| Age Group | Caverject/MUSE | Prostin VR Pediatric IV | Evidence Level | |---|---|---|---| | Neonates (0 to 28 days) | Not indicated, no data | FDA-approved; 0.05 mcg/kg/min start | Class I, Level B-NR (AHA 2021) | | Infants (1 to 12 months) | Not indicated, no data | FDA-approved continuation; titrate to lowest effective dose | Class I, Level B-NR | | Toddlers/Children (1 to 12 years) | Not indicated, no data | Off-label only; case-report doses 0.01 to 0.05 mcg/kg/min | Level of evidence: case reports only | | Adolescents (12 to 17 years) | Not indicated per labeling | Off-label only | No controlled data |

Drug Interactions and Contraindications Relevant to Pediatric Patients

Alprostadil IV potentiates the hypotensive effects of other vasodilators commonly used in neonatal cardiac care, including milrinone and nitroprusside. [24] Concurrent use requires more frequent blood pressure checks, typically every 15 minutes during dose adjustments. [12]

Indomethacin, which is used to close a patent ductus arteriosus in premature neonates, directly opposes the pharmacological action of PGE1. These agents should not be co-administered. [25] The physiological tension between these drugs reflects their opposing roles in ductal tone regulation.

Heparin is frequently co-infused through the same IV line in neonatal ICU patients. While no pharmacokinetic interaction with alprostadil has been formally documented, institutional protocols typically recommend separate IV lines to avoid precipitation risks with concentrated electrolyte solutions. [12]

No pediatric pharmacokinetic studies of Caverject or MUSE exist. For Prostin VR Pediatric, alprostadil is rapidly metabolized in the pulmonary vasculature, with approximately 68% of a circulating dose cleared in a single pass through the lungs. [1] This rapid clearance supports the need for continuous infusion rather than intermittent dosing.

Regulatory and Prescribing Considerations for Off-Label Pediatric Use

When Caverject or MUSE is prescribed for a patient under 12 for any reason, the prescriber bears full responsibility under FDA off-label prescribing regulations. The FDA's guidance on off-label drug use states that physicians may prescribe any approved drug for unapproved uses based on sound medical evidence, but that the prescriber must inform the patient (or guardian) that the use is not FDA-approved. [26]

The FDA's Office of Pediatric Therapeutics provides a framework under 21 CFR Part 201 for labeling drugs that lack pediatric data; Caverject and MUSE carry the standard notation that "safety and effectiveness in pediatric patients have not been established." [2] [3] This notation does not prohibit prescribing but signals the absence of supportive data.

Institutional review: Most academic medical centers require pharmacy and therapeutics committee approval before dispensing Caverject or MUSE for a patient under 18. Clinicians should confirm their institution's specific policy before initiating any such prescription. [27]

The American Academy of Pediatrics Committee on Drugs has published general guidance on off-label drug use in children, noting that off-label prescribing accounts for approximately 75% of pediatric drug orders in hospital settings, though this figure does not imply the practice is without risk. [28]

Practical Clinical Guidance for the Prescribing Clinician

For a neonate with suspected ductus-dependent congenital heart disease, initiate Prostin VR Pediatric at 0.05 mcg/kg/min before echocardiographic confirmation if clinical suspicion is high and the patient is deteriorating. [6] Do not delay for confirmatory imaging in an unstable neonate.

Titrate by doubling the dose every 15 to 30 minutes (0.05, then 0.1, then 0.2 mcg/kg/min) if oxygenation does not improve. [10] Once the target pO2 or blood pressure is achieved, step the infusion back down to the lowest effective rate to minimize apnea risk. [1]

Have bag-mask ventilation equipment at bedside before starting the infusion. Intubation equipment should be immediately available for any neonate under 2 kg. [1]

Document the infusion rate, patient weight, dilution concentration, and monitoring parameters in the medical record every hour during active titration and every four hours during stable maintenance therapy. [12]

For any inquiry about Caverject or MUSE in a child under 12, document that no approved dosing exists, that the indication (erectile dysfunction) is absent in this age group, and that the prescribing clinician declined to provide an off-label dose. Refer the clinical question to pediatric urology if an underlying urological condition is driving the query.